Brief: Reata Announces FDA Accepted For Filing The NDA For Bardoxolone For The Treatment Of Patients With Chronic Kidney Disease Caused By Alport Syndrome
26/04/2021 22:18
Reata Pharmaceuticals Inc RETA.O :
* REATA ANNOUNCES FDA ACCEPTED FOR FILING THE NDA FOR
BARDOXOLONE
FOR THE TREATMENT OF PATIENTS WITH CHRONIC KIDNEY DISEASE CAUSED
BY ALPORT SYNDROME
* REATA PHARMACEUTICALS INC - APPLICATION ASSIGNED A PDUFA
DATE
OF FEBRUARY 25, 2022 FOR BARDOXOLONE
Source text for Eikon: ID:nGNX8fgLbh
Further company coverage: RETA.O
Recent news on Reata Pharmaceuticals
See all newsReata Pharmaceuticals Inc reports results for the quarter ended in June - Earnings Summary
Reata Pharmaceuticals Inc expected to post a loss of $2.88 a share - Earnings Preview
Brief: Biogen Inc Says If Deal Terminated Under Certain Conditions, Reata Will Be Required To Pay Biogen Termination Fee Equal To $264 Mln
U.S. STOCKS ON THE MOVE-US regional banks, Enphase, Centene
Biogen’s $7 bln deal goes smaller and safer